Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (321-330 of 487) with videos related to

Pageof 49
Sort By:
Oncotarget|March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusXiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapyMilan Radovich, James Wacker, Jeffrey Solzak, et al.
Cancer|July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsGoldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersMuhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Cancer|December 10, 2015
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Kai Wang, Depinder Khaira, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Pageof 49

Showing results (321-330 of 487) with videos related to

Sort By:
Pageof 49
Oncotarget|March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusXiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapyMilan Radovich, James Wacker, Jeffrey Solzak, et al.
Cancer|July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsGoldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersMuhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Cancer|December 10, 2015
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Kai Wang, Depinder Khaira, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Pageof 49